Menstrual migraine. Diagnosis, pathogenesis and review of acute and short-term prevention pharmacotherapy
DOI:
https://doi.org/10.12775/JEHS.2024.75.55840Keywords
menstrual migraine, acute treatment, prevention, triptans, lasmiditan, CGRP monoclonal antibodiesAbstract
Background
Menstrual migraine describes migraines that occur in alignment with the menstrual cycle, affecting women of diverse age ranges. This condition is relatively common, presenting a unique challenge due to the heightened intensity of pain during these attacks. Additionally, these migraines are often more resistant to standard treatment methods, underscoring the need for specialized approaches to management and relief.
Methods
Review of double-blind, placebo-controlled cohort studies found using PubMed, Google Scholar and Cochrane.
Results
Triptans are considered a primary treatment option for managing acute menstrual migraine episodes, with their effectiveness being the most extensively researched among available therapies. Recently, lasmiditan has emerged as a newer medication showing promising potential for this specific application as well, adding to the options available for menstrual migraine relief.
Furthermore, triptans have been validated as effective in the short-term prevention of migraine. The most recent pharmacological advancements that have demonstrated efficacy for this condition are monoclonal antibodies which target the CGRP receptor: Erenumab and Galcanezumab.
Conclusion
There are effective approaches to both treating and preventing acute migraine attacks. However, menstrual migraine is a condition that requires greater awareness and recognition, as this would allow for the improved and more effective use of existing medications and treatments.
References
Aguilar-Shea AL, Membrilla Md JA, Diaz-de-Teran J. Migraine review for general practice. Aten Primaria. 2022 Feb;54(2):102208. doi: 10.1016/j.aprim.2021.102208. Epub 2021 Nov 16. PMID: 34798397; PMCID: PMC8605054.
Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017 Jan;16(1):76-87. doi: 10.1016/S1474-4422(16)30293-9. Epub 2016 Nov 9. PMID: 27836433.
Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z; Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0. PMID: 33267788; PMCID: PMC7708887.
Ashina M, Terwindt GM, Al-Karagholi MA, de Boer I, Lee MJ, Hay DL, Schulte LH, Hadjikhani N, Sinclair AJ, Ashina H, Schwedt TJ, Goadsby PJ. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet. 2021 Apr 17;397(10283):1496-1504. doi: 10.1016/S0140-6736(20)32162-0. Epub 2021 Mar 25. PMID: 33773610.
Lucas C. Migraine with aura. Rev Neurol (Paris). 2021 Sep;177(7):779-784. doi: 10.1016/j.neurol.2021.07.010. Epub 2021 Aug 9. PMID: 34384631.
Olson AK, Hansen KA. Menstrual Migraines: Diagnosis, Evidence, and Treatment. S D Med. 2021 Dec;74(12):570-575. PMID: 35015948.
Raffaelli B, Do TP, Chaudhry BA, Ashina M, Amin FM, Ashina H. Menstrual migraine is caused by estrogen withdrawal: revisiting the evidence. J Headache Pain. 2023 Sep 21;24(1):131. doi: 10.1186/s10194-023-01664-4. PMID: 37730536; PMCID: PMC10512516.
Nappi RE, Tiranini L, Sacco S, De Matteis E, De Icco R, Tassorelli C. Role of Estrogens in Menstrual Migraine. Cells. 2022 Apr 15;11(8):1355. doi: 10.3390/cells11081355. PMID: 35456034; PMCID: PMC9025552.
Barra M, Dahl FA, MacGregor EA, Vetvik KG. Identifying menstrual migraine- improving the diagnostic criteria using a statistical method. J Headache Pain. 2019 Sep 6;20(1):95. doi: 10.1186/s10194-019-1035-7. PMID: 31492101; PMCID: PMC6734306.
Verhagen IE, Spaink HA, van der Arend BW, van Casteren DS, MaassenVanDenBrink A, Terwindt GM. Validation of diagnostic ICHD-3 criteria for menstrual migraine. Cephalalgia. 2022 Oct;42(11-12):1184-1193. doi: 10.1177/03331024221099031. Epub 2022 May 6. PMID: 35514214; PMCID: PMC9535967.
Granella F, Sances G, Allais G, Nappi RE, Tirelli A, Benedetto C, Brundu B, Facchinetti F, Nappi G. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004 Sep;24(9):707-16. doi: 10.1111/j.1468-2982.2004.00741.x. PMID: 15315526.
Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021 Oct 1;4(10):e2128544. doi: 10.1001/jamanetworkopen.2021.28544. PMID: 34633423; PMCID: PMC8506232.
Ong JJY, De Felice M. Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action. Neurotherapeutics. 2018 Apr;15(2):274-290. doi: 10.1007/s13311-017-0592-1. Erratum in: Neurotherapeutics. 2018 Apr;15(2):525-526. doi: 10.1007/s13311-017-0599-7. PMID: 29235068; PMCID: PMC5935632.
Khoo CC, Liu CC, Lu M, Huang YC, Weng HY. Acute and preventive treatment of menstrual migraine: a meta-analysis. J Headache Pain. 2024 Sep 4;25(1):143. doi: 10.1186/s10194-024-01848-6. PMID: 39227797; PMCID: PMC11373287.
Doty EG, Krege JH, Jin L, Raskin J, Halker Singh RB, Kalidas K. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine. Cephalalgia. 2019 Oct;39(12):1569-1576. doi: 10.1177/0333102419859313. Epub 2019 Jul 3. PMID: 31266353; PMCID: PMC6791026.
Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, Xu YC. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010 Oct;30(10):1159-69. doi: 10.1177/0333102410370873. Epub 2010 Jun 15. PMID: 20855361.
Vila-Pueyo M. Targeted 5-HT1F Therapies for Migraine. Neurotherapeutics. 2018 Apr;15(2):291-303. doi: 10.1007/s13311-018-0615-6. PMID: 29488143; PMCID: PMC5935644.
MacGregor EA. Estrogen replacement and migraine. Maturitas. 2009 May 20;63(1):51-5. doi: 10.1016/j.maturitas.2009.03.016. Epub 2009 Apr 16. PMID: 19375252.
MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004 Jun;3(6):354-61. doi: 10.1016/S1474-4422(04)00768-9. PMID: 15157850.
MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006 Dec 26;67(12):2154-8. doi: 10.1212/01.wnl.0000233888.18228.19. Epub 2006 Sep 13. PMID: 16971700.
Draper CF, Duisters K, Weger B, Chakrabarti A, Harms AC, Brennan L, Hankemeier T, Goulet L, Konz T, Martin FP, Moco S, van der Greef J. Menstrual cycle rhythmicity: metabolic patterns in healthy women. Sci Rep. 2018 Oct 1;8(1):14568. doi: 10.1038/s41598-018-32647-0. Erratum in: Sci Rep. 2019 Apr 3;9(1):5797. doi: 10.1038/s41598-019-41392-x. PMID: 30275458; PMCID: PMC6167362.
Vetvik KG, MacGregor EA. Menstrual migraine: a distinct disorder needing greater recognition. Lancet Neurol. 2021 Apr;20(4):304-315. doi: 10.1016/S1474-4422(20)30482-8. Epub 2021 Feb 15. PMID: 33600767.
Martin VT, Wernke S, Mandell K, Ramadan N, Kao L, Bean J, Liu J, Zoma W, Rebar R. Defining the relationship between ovarian hormones and migraine headache. Headache. 2005 Oct;45(9):1190-201. doi: 10.1111/j.1526-4610.2005.00242.x. PMID: 16178949.
Paredes S, Cantillo S, Candido KD, Knezevic NN. An Association of Serotonin with Pain Disorders and Its Modulation by Estrogens. Int J Mol Sci. 2019 Nov 15;20(22):5729. doi: 10.3390/ijms20225729. PMID: 31731606; PMCID: PMC6888666.
Smith YR, Stohler CS, Nichols TE, Bueller JA, Koeppe RA, Zubieta JK. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci. 2006 May 24;26(21):5777-85. doi: 10.1523/JNEUROSCI.5223-05.2006. PMID: 16723535; PMCID: PMC1808228.
González SL, Meyer L, Raggio MC, Taleb O, Coronel MF, Patte-Mensah C, Mensah-Nyagan AG. Allopregnanolone and Progesterone in Experimental Neuropathic Pain: Former and New Insights with a Translational Perspective. Cell Mol Neurobiol. 2019 May;39(4):523-537. doi: 10.1007/s10571-018-0618-1. Epub 2018 Sep 5. PMID: 30187261.
Cutrer FM, Moskowitz MA. Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache. 1996 Nov-Dec;36(10):579-85. doi: 10.1046/j.1526-4610.1996.3610579.x. PMID: 8990596.
Eikermann-Haerter K, Kudo C, Moskowitz MA. Cortical spreading depression and estrogen. Headache. 2007 Sep;47 Suppl 2:S79-85. doi: 10.1111/j.1526-4610.2007.00818.x. PMID: 17850538.
Puri V, Cui L, Liverman CS, Roby KF, Klein RM, Welch KM, Berman NE. Ovarian steroids regulate neuropeptides in the trigeminal ganglion. Neuropeptides. 2005 Aug;39(4):409-17. doi: 10.1016/j.npep.2005.04.002. PMID: 15936815.
Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010 Oct;6(10):573-82. doi: 10.1038/nrneurol.2010.127. Epub 2010 Sep 7. PMID: 20820195.
Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013 Nov;14(11):1289-303. doi: 10.1016/j.jpain.2013.03.010. Epub 2013 Aug 17. PMID: 23958278.
Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014 Oct;94(4):1099-142. doi: 10.1152/physrev.00034.2013. PMID: 25287861; PMCID: PMC4187032.
Stevenson JC, Macdonald DW, Warren RC, Booker MW, Whitehead MI. Increased concentration of circulating calcitonin gene related peptide during normal human pregnancy. Br Med J (Clin Res Ed). 1986 Nov 22;293(6558):1329-30. doi: 10.1136/bmj.293.6558.1329. PMID: 3098339; PMCID: PMC1342049.
Yallampalli C, Chauhan M, Thota CS, Kondapaka S, Wimalawansa SJ. Calcitonin gene-related peptide in pregnancy and its emerging receptor heterogeneity. Trends Endocrinol Metab. 2002 Aug;13(6):263-9. doi: 10.1016/s1043-2760(02)00563-5. PMID: 12128288.
Valdemarsson S, Edvinsson L, Hedner P, Ekman R. Hormonal influence on calcitonin gene-related peptide in man: effects of sex difference and contraceptive pills. Scand J Clin Lab Invest. 1990 Jun;50(4):385-8. doi: 10.3109/00365519009091595. PMID: 2392651.
Gupta P, Harte A, Sturdee DW, Sharma A, Barnett AH, Kumar S, McTernan PG. Effects of menopausal status on circulating calcitonin gene-related peptide and adipokines: implications for insulin resistance and cardiovascular risks. Climacteric. 2008 Oct;11(5):364-72. doi: 10.1080/13697130802378493. PMID: 18781480.
Downie J, Poyser NL, Wunderlich M. Levels of prostaglandins in human endometrium during the normal menstrual cycle. J Physiol. 1974 Jan;236(2):465-72. doi: 10.1113/jphysiol.1974.sp010446. PMID: 16992446; PMCID: PMC1350813.
Abreu-Sánchez A, Parra-Fernández ML, Onieva-Zafra MD, Ramos-Pichardo JD, Fernández-Martínez E. Type of Dysmenorrhea, Menstrual Characteristics and Symptoms in Nursing Students in Southern Spain. Healthcare (Basel). 2020 Aug 26;8(3):302. doi: 10.3390/healthcare8030302. PMID: 32858887; PMCID: PMC7551507.
Mannix LK. Menstrual-related pain conditions: dysmenorrhea and migraine. J Womens Health (Larchmt). 2008 Jun;17(5):879-91. doi: 10.1089/jwh.2007.0440. PMID: 18537489.
Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandin E(2) induces immediate migraine-like attack in migraine patients without aura. Cephalalgia. 2012 Aug;32(11):822-33. doi: 10.1177/0333102412451360. Epub 2012 Jun 19. PMID: 22718556.
Sutherland HG, Champion M, Plays A, Stuart S, Haupt LM, Frith A, MacGregor EA, Griffiths LR. Investigation of polymorphisms in genes involved in estrogen metabolism in menstrual migraine. Gene. 2017 Apr 5;607:36-40. doi: 10.1016/j.gene.2017.01.008. Epub 2017 Jan 13. PMID: 28089731.
Rodriguez-Acevedo AJ, Smith RA, Roy B, Sutherland H, Lea RA, Frith A, MacGregor EA, Griffiths LR. Genetic association and gene expression studies suggest that genetic variants in the SYNE1 and TNF genes are related to menstrual migraine. J Headache Pain. 2014 Oct 14;15(1):62. doi: 10.1186/1129-2377-15-62. PMID: 25315199; PMCID: PMC4196204.
Pollock CE, Sutherland HG, Maher BH, Lea RA, Haupt LM, Frith A, Anne MacGregor E, Griffiths LR. The NRP1 migraine risk variant shows evidence of association with menstrual migraine. J Headache Pain. 2018 Apr 18;19(1):31. doi: 10.1186/s10194-018-0857-z. PMID: 29671086; PMCID: PMC5906416.
Headache Classifcation Committee of the International Headache Society (IHS) (2018) The international classifcation of headache disorders, 3rd edition. Cephalalgia 38:1–211
Silberstein SD, Massiou H, Le Jeunne C, Johnson-Pratt L, McCarroll KA, Lines CR. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol. 2000 Aug;96(2):237-42. doi: 10.1016/s0029-7844(00)00880-2. PMID: 10908770.
Mannix LK, Loder E, Nett R, Mueller L, Rodgers A, Hustad CM, Ramsey KE, Skobieranda F. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007 May;27(5):414-21. doi: 10.1111/j.1468-2982.2007.01313.x. PMID: 17448179.
Martin V, Cady R, Mauskop A, Seidman LS, Rodgers A, Hustad CM, Ramsey KE, Skobieranda F. Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies. Headache. 2008 Feb;48(2):226-35. doi: 10.1111/j.1526-4610.2007.00947.x. Epub 2007 Nov 13. PMID: 18005144.
Allais G, Bussone G, D'Andrea G, Moschiano F, d'Onofrio F, Valguarnera F, Manzoni GC, Grazzi L, Allais R, Benedetto C, Acuto G. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2011 Jan;31(2):144-51. doi: 10.1177/0333102410378048. Epub 2010 Jul 26. PMID: 20660540; PMCID: PMC3057443.
Diamond ML, Cady RK, Mao L, Biondi DM, Finlayson G, Greenberg SJ, Wright P. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. Headache. 2008 Feb;48(2):248-58. doi: 10.1111/j.1526-4610.2007.01019.x. PMID: 18234046.
Allais G, Acuto G, Cabarrocas X, Esbri R, Benedetto C, Bussone G. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci. 2006 May;27 Suppl 2:S193-7. doi: 10.1007/s10072-006-0600-4. PMID: 16688629.
Tuchman M, Hee A, Emeribe U, Silberstein S. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20(12):1019-26. doi: 10.2165/00023210-200620120-00005. PMID: 17140280.
Allais G, Tullo V, Benedetto C, Zava D, Omboni S, Bussone G. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurol Sci. 2011 May;32 Suppl 1(Suppl 1):S99-104. doi: 10.1007/s10072-011-0547-y. PMID: 21533723; PMCID: PMC3084939.
Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B, Savi L, Pini LA, Sances G, Santoro P, Zanchin G, Omboni S, Ferrari MD, Fierro B, Brighina F. Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. J Headache Pain. 2012 Jul;13(5):401-6. doi: 10.1007/s10194-012-0455-4. Epub 2012 May 17. PMID: 22592864; PMCID: PMC3381066.
Savi L, Omboni S, Lisotto C, Zanchin G, Ferrari MD, Zava D, Pinessi L. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. J Headache Pain. 2011 Dec;12(6):609-15. doi: 10.1007/s10194-011-0366-9. Epub 2011 Aug 13. PMID: 21842274; PMCID: PMC3208043.
Allais G, Bussone G, Tullo V, Cortelli P, Valguarnera F, Barbanti P, Sette G, D'Onofrio F, Curone M, Benedetto C. Frovatriptan 2.5 mg plus dexketoprofen (25 mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial. Cephalalgia. 2015 Jan;35(1):45-50. doi: 10.1177/0333102414542290. Epub 2014 Jul 22. PMID: 25053749; PMCID: PMC4261077.
Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel C; French Naramig Collaborative Study Group. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol. 2005 Oct;12(10):774-81. doi: 10.1111/j.1468-1331.2005.01076.x. PMID: 16190915.
Dowson AJ, Massiou H, Aurora SK. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. J Headache Pain. 2005 Apr;6(2):81-7. doi: 10.1007/s10194-005-0156-3. Epub 2005 Apr 8. PMID: 16362647; PMCID: PMC3452313.
Landy S, Savani N, Shackelford S, Loftus J, Jones M. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract. 2004 Oct;58(10):913-9. doi: 10.1111/j.1368-5031.2004.00295.x. PMID: 15587768.
Mannix LK, Martin VT, Cady RK, Diamond ML, Lener SE, White JD, Derosier FJ, McDonald SA. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol. 2009 Jul;114(1):106-113. doi: 10.1097/AOG.0b013e3181a98e4d. PMID: 19546766.
MacGregor EA, Komori M, Krege JH, Baygani S, Vincent M, Pavlovic J, Igarashi H. Efficacy of lasmiditan for the acute treatment of perimenstrual migraine. Cephalalgia. 2022 Dec;42(14):1467-1475. doi: 10.1177/03331024221118929. Epub 2022 Aug 18. PMID: 35979677; PMCID: PMC9693902.
Newman L, Mannix LK, Landy S, Silberstein S, Lipton RB, Putnam DG, Watson C, Jöbsis M, Batenhorst A, O'Quinn S. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache. 2001 Mar;41(3):248-56. doi: 10.1046/j.1526-4610.2001.111006248.x. PMID: 11264684.
Mannix LK, Savani N, Landy S, Valade D, Shackelford S, Ames MH, Jones MW. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache. 2007 Jul-Aug;47(7):1037-49. doi: 10.1111/j.1526-4610.2007.00855.x. PMID: 17635595.
Silberstein SD, Berner T, Tobin J, Xiang Q, Campbell JC. Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation. Headache. 2009 Oct;49(9):1283-97. doi: 10.1111/j.1526-4610.2009.01509.x. Epub 2009 Sep 14. PMID: 19751371.
Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004 Jul 27;63(2):261-9. doi: 10.1212/01.wnl.0000134620.30129.d6. PMID: 15277618.
Brandes JL, Poole Ac, Kallela M, Schreiber CP, MacGregor EA, Silberstein SD, Tobin J, Shaw R. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia. 2009 Nov;29(11):1133-48. doi: 10.1111/j.1468-2982.2009.01840.x. PMID: 19811503.
Tuchman MM, Hee A, Emeribe U, Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs. 2008;22(10):877-86. doi: 10.2165/00023210-200822100-00007. PMID: 18788838.
Igarashi H, Shibata M, Ozeki A, Matsumura T. Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial. Neurol Ther. 2023 Feb;12(1):73-87. doi: 10.1007/s40120-022-00410-3. Epub 2022 Oct 20. PMID: 36266558; PMCID: PMC9837349.
Pavlovic JM, Paemeleire K, Göbel H, Bonner J, Rapoport A, Kagan R, Zhang F, Picard H, Mikol DD. Efficacy and safety of erenumab in women with a history of menstrual migraine. J Headache Pain. 2020 Aug 3;21(1):95. doi: 10.1186/s10194-020-01167-6. PMID: 32746775; PMCID: PMC7398400.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Daria Furtak, Wiktor Grela, Jagoda Niewiadomska, Dawid Tulej, Paulina Głogowska, Alicja Dziedzic, Natalia Gniaź, Dominika Marciniuk, Natalia Marko, Aleksandra Górska

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 111
Number of citations: 0